Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 34

recruiting
3 970
countries
28
conditions
2 124

10 522 trials match your criteria

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Drocamorelin

Study of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Soquelitinib

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trilaciclib dihydrochloride

Study of dienogest and drospirenone on ovulation inhibition for pregnancy prevention in healthy premenopausal women

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Dienogest

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Obesity

Recruiting

A study of NNC0638-0355 to evaluate safety, tolerability and weight loss with multiple doses in adults with obesity or overweight

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:NNC0638-0355

Bladder cancer

Recruiting

Long‑Term Follow‑Up of Mitomycin (UGN‑103) Treatment in Patients with Recurrent Low‑Grade Intermediate‑Risk Non‑Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin

Obesity

Recruiting

Phase 2b Randomized Study of Semaglutide Subcutaneous Depot for Weight Reduction in Adults with Obesity or Overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.